Microflora Disturbance during Progression of Glucose Intolerance and Effect of Sitagliptin: An Animal Study
Open accessThe DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Abstract
Background. Emerging evidences have shown a close interplay between obesity, diabetes, and intestinal flora disturbance. Dipeptidyl peptidase-4 inhibitor, exemplified by sitagliptin, is highly efficacious in treating type 2 diabetes (T2DM), yet little is known if sitagliptin exerts beneficial effects on microbiota associated with obesity and T2DM. We evaluated changes of gut microbiota following the induction of obesity and T2DM in a streptozotocin treated high fat/high carbohydrate fed (HF/HC-STZ) rat model and explored the effect of sitagliptin on gut microbiota for HF/HC-STZ rats.Methods. Sitagliptin was administered via oral gavage to diabetic rats. Fecal DNA extraction and 454 pyrosequencing based on analysis of 16S rRNA genes was utilized to determine the overall structure of microbiota in fecal DNA samples.Results. Results showed that, at the level of phylum, there was higher abundance of Firmicutes and Tenericutes and less abundance of Bacteroidetes in obese rats compared to their lean counterparts. At the level of genus, short-chain fatty acid- (SCFA-) producing bacteria,Blautia,Roseburia, and Clostridium, and probiotics Lactobacillus,Bifidobacterium, and so forth were identified significantly different from each other among conditions.Conclusion. Marked shifts of the gut microbiota structure were observed in the rats during development of glucose intolerance. Intestinal flora changed in the process of glucose intolerance, and treatment of sitagliptin moderately corrected the dysbiosis of microbiota in T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, DPP-4 inhibitors are also able to modify gut microbiota by increasing Firmicutes and Tenericutes phyla and decreasing Bacteroidetes in DIO rodents [307].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [307]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Gut Microbiota Is a Key Modulator of Insulin Resistance in TLR 2 Knockout Mice
Caricilli, A. M., Picardi, P. K., de Abreu, L. L., Ueno, M., Prada, P. O., Ropelle, E. R., Hirabara, S. M., Castoldi, Â., Vieira, P., Camara, N. O. S., et al. (2011) · PLoS Biology · doi:10.1371/journal.pbio.1001212 · Cited by 282 · cited 1×
“The associations between microbiota and obesity, insulin resistance, and diabetes are presumably due to the impaired ability of the microbes to extract energy from the diet [9], altered fatty acid metabolism [11], changes in secretion of gut hormones such as peptide YY (PYY) [12], activation of lipopolysaccharide toll…”
BackgroundRetractedSchloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
Diversity of the Human Intestinal Microbial Flora
Eckburg, P. B., Bik, E. M., Bernstein, C. N., Purdom, E., Dethlefsen, L., Sargent, M., Gill, S. R., Nelson, K. E., & Relman, D. A. (2005) · Science · doi:10.1126/science.1110591 · Cited by 7,913
A core gut microbiome in obese and lean twins
Turnbaugh, P. J., Hamady, M., Yatsunenko, T., Cantarel, B. L., Duncan, A., Ley, R. E., Sogin, M. L., Jones, W. J., Roe, B. A., Affourtit, J. P., et al. (2009) · Nature · doi:10.1038/nature07540 · Cited by 7,823
A metagenome-wide association study of gut microbiota in type 2 diabetes
Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., Liang, S., Zhang, W., Guan, Y., Shen, D., et al. (2012) · Nature · doi:10.1038/nature11450 · Cited by 6,762
The gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245
Obesity alters gut microbial ecology
Ley, R. E., Bäckhed, F., Turnbaugh, P., Lozupone, C. A., Knight, R. D., & Gordon, J. I. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504978102 · Cited by 6,176 · cited 1×
“Implantation of gut flora from obese mice to normal and germfree mice resulted in increased body weight and insulin resistance [9, 10] supporting the notion that the bacterial species from obese gut have metabolically unfavorable properties.”
BackgroundDe Filippo, C., Cavalieri, D., Di Paola, M., Ramazzotti, M., Poullet, J. B., Massart, S., Collini, S., Pieraccini, G., & Lionetti, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005963107 · Cited by 5,579 · cited 1×
“SCFA-producing bacteria have been previously shown to benefit the host through protecting the mucosa from damage induced by pathogens, supplying colonocyte nutrients, mitigating inflammation, and so forth [39, 40].”
BackgroundMetagenomic Analysis of the Human Distal Gut Microbiome
Gill, S. R., Pop, M., DeBoy, R. T., Eckburg, P. B., Turnbaugh, P. J., Samuel, B. S., Gordon, J. I., Relman, D. A., Fraser-Liggett, C. M., & Nelson, K. E. (2006) · Science · doi:10.1126/science.1124234 · Cited by 4,699 · cited 1×
“Among available methodologies to study the microbial ecology of complex bacterial communities, the so-called metagenomics approach is considered to be the “golden standard” [18, 19].”
Background
Research works printed but not linked: 1
- Zhou Y. S. Gao Y. Li B. A rat model of type 2 diabetes mellitus induced by high fat chow and low dose streptozocin injection Acta Laboratorium Animals Scientia Sinica 2005 13 3 154 158
Cited by
Items 101–110 of 110
A pro-, pre- és szinbiotikumok hatása a szénhidrát-, illetve lipidanyagcserére
Tomasics, G., Schandl, L., Polyák, A., & Winkler, G. (2024) · Orvosi Hetilap · doi:10.1556/650.2024.33064 · Cited by 1
Medication and Health Risks Associated With Neglected Side Effects on Gut Microbiota
Velikova, T. V., Nakov, R., & Ianiro, G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00074-7 · Cited by 1
Study on Diabetic Rats Comparing the Effects of Sitagliptin and Probiotics on Serum Glucose
Lateef, N., Rehman, I., Tahir, M., Tahir, M. N., ., A., & Memon, F. A. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs221651135
If drugs with metabolic action affect the intestinal microbiota. Literature review
Fadieienko, G. D., Gridnyev, O., & Gridneiva, S. V. (2022) · Modern Gastroenterology · doi:10.30978/mg-2022-1-37
Medicinal-microbial interactions and ways of correcting iatrogenic intestinal dysbiosis
Бакулин, И. Г., & Serkova, M. Y. (2023) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-207-11-26-35 · Cited by 1
Sinyushkina, S. D., Gorinova, A. V., Belousova, A. S., Sorokina, Y. А., & Занозина, О. В. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-386
Gut Microbiota in Type 2 Diabetes
Ganguly, A., & Patra, F. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815324549125010008
Li, M., Cheng, D., Peng, C., Huang, Y., Geng, J., Huang, G., Wang, T., & Xu, A. (2023) · Figshare · doi:10.6084/m9.figshare.22949421
Łoniewski, I., Szulińska, M., Kaczmarczyk, M., Podsiadło, K., Styburski, D., Skonieczna‐Żydecka, K., & Bogdański, P. (2024) · Figshare · doi:10.6084/m9.figshare.26553089
Chang, Y., Zhou, Y., Zhou, F., Liang, J., Yang, G., Zhang, P., & Tian, M. (2026) · Journal of Endocrinology · doi:10.1530/joe-26-0110
Metadata
- Authors
- Yan, X., Feng, B., Li, P., Tang, Z., & Wang, L.
- Affiliations
- Tongji University (CN)
- Corresponding author
- Feng, Bo
- Venue
- Journal of Diabetes Research
- Publisher
- Wiley
- Published
- 2016
- Volume
- 2016
- Pages
- 1-10
- ISSN
- 2314-6745 (ISSN-L)
- 2314-6753
- PMC
- PMC5007364
- OpenAlex
- W2518629454
- Cited by
- 110
- References
- 52
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 10 · 2023: 13 · 2022: 19 · 2021: 16 · 2020: 11 · 2019: 15 · 2018: 8 · 2017: 6
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal of Diabetes Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Basic Research Program of China (2011CB504006, PWZz2013-04, 12030510351)
- Pudong Health and Family Planning Commission of Shanghai (2011CB504006, PWZz2013-04, 12030510351)
- Chinese Medical Association (2011CB504006, PWZz2013-04, 12030510351)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- gut microbiota, sitagliptin, type 2 diabetes, impaired glucose tolerance, obesity, DPP-4 inhibitors, dysbiosis, Firmicutes, Bacteroidetes, short-chain fatty acid-producing bacteria, high-fat high-carbohydrate diet, streptozotocin-induced diabetes, rat model
- MeSH terms
- Sitagliptin Phosphate, Gastrointestinal Microbiome, Animals, Blood Glucose, Body Weight, Hypoglycemic Agents, Glucose Intolerance, Disease Progression, Diabetes Complications, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.